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The X-linkedFoxp3 is a member of the forkhead/
winged helix transcription factor family. Germ-
line mutations cause lethal autoimmune dis-
eases in males. Serendipitously, we observed
that female mice heterozygous for the ‘‘scurfin’’
mutation of the Foxp3 gene (Foxp3sf/+) devel-
oped cancer at a high rate. The majority of the
cancers were mammary carcinomas in which
the wild-type Foxp3 allele was inactivated and
HER-2/ErbB2was overexpressed. Foxp3 bound
and repressed theHER-2/ErbB2promoter. Dele-
tion, functionally significant somatic mutations,
and downregulation of the FOXP3 gene were
commonly found in human breast cancer sam-
ples and correlated significantly with HER-2/
ErbB2 overexpression, regardless of the status
of HER-2 amplification. Our data demonstrate
that FOXP3 is an X-linked breast cancer sup-
pressor gene and an important regulator of the
HER-2/ErbB2 oncogene.
INTRODUCTION
Identification of BRCA1 and BRCA2marks a key advance
in understanding the genetic defects responsible for
breast cancer (Miki et al., 1994; Wooster et al., 1995). Sev-
eral other genes, such as TP53, PIK3CA, and PTEN, have
also been implicated in familial and sporadic cancers
(Samuels et al., 2004; Wooster and Weber, 2003). How-ever, the genetic defects for breast cancer have yet to be
fully elucidated. There is an important distinction between
autosomal and X-linked genes, asmany genes in the latter
category are subject to X inactivation, making it easier
to fulfill Knudson’s two-hit theory (Knudson, 1971). As
such, X-linked tumor suppressor genes can potentially
be more important, as LOH or mutation of a single allele
can in effect functionally silence the gene (Spatz et al.,
2004). However, essentially all tumor suppressor genes
are autosomal (Spatz et al., 2004), although tantalizing
evidence concerning abnormalities in the X chromosome,
including LOH, skewed inactivation, and selective loss,
has been reported in breast cancer samples (Kristiansen
et al., 2005; Piao and Malkhosyan, 2002; Richardson
et al., 2006; Roncuzzi et al., 2002).
HER-2/Neu/ErbB2 is one of the first oncogenes to be
identified (Schechter et al., 1984) and has been demon-
strated to be expressed in a large proportion of cancer
cells (Garcia de Palazzo et al., 1993). The level of HER-2/
NEU is an important prognostic marker (Slamon et al.,
1987). Anti-HER-2/NEU antibody Herceptin has emerged
as an important therapeutic for patients with overex-
pressed HER-2/NEU on cancer tissues (Slamon et al.,
2001). Given the clinical and therapeutic significance of
Her-2/Neu/ErbB2 overexpression, it is important to iden-
tify the molecular mechanisms responsible for the overex-
pression. A well-established mechanism responsible for
HER-2 overexpression in human cancer is gene amplifica-
tion (Slamon et al., 1987). However, it is unclear whether
gene amplification alone is sufficient to cause HER-2 over-
expression. Moreover, a significant proportion of human
cancers with moderate overexpression of HER-2 does
not show gene amplification (Bofin et al., 2004; JimenezCell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc. 1275
Figure 1. Increased Susceptibility to
Breast Cancer in Mice Heterozygous for
Foxp3sf
(A) Representative breast cancers developed in
female Foxp3sf/+Otcspf/+ mice. The top panel
shows the gross anatomy,while the lower panel
shows the histology of local and metastatic
lesions of a breast cancer. (B) Cancer-free
survival analysis of Foxp3sf/+, Foxp3sf/+Otcspf/+,
Otcspf/+, and WT littermates. Mice were sacri-
ficed when moribund to identify the tissue
origins of cancers. Foxp3sf/+ versus WT, p <
0.0001; Foxp3sf/+ versus Otcspf/+, p = 0.0003;
Foxp3sf/+ versus Foxp3sf/+Otcspf/+, p = 0.9526;
Foxp3sf/+Otcspf/+ versusWT, p = 0.0001; Foxp3sf/+
Otcspf/+ versus Otcspf/+, p = 0.0001; Otcspf/+
versus WT, p = 0.4164.
(C) As in (B), except that only incidences of
mammary tumors were included. Foxp3sf/+
versus WT, p = 0.00015; Foxp3sf/+Otcspf/+
versus WT, p = 0.00011.
(D) Increased susceptibility of Foxp3sf/+mice to
carcinogen DMBA and progesterone. The dia-
gram on top depicts experimental protocol,
while survival analysis is shown in the bottom
panel. Foxp3sf/+ versus WT, p < 0.0001;
Foxp3sf/+Otcspf/+ versus Otcspf/+, p = 0.0005;
Otcspf/+ versus WT, p = 0.8157. In (B) and (C),
those mice that were observed for only part of
the duration were incorporated as censored
samples and were marked with a cross in the
Kaplan-Meier survival curves. The p values in
(B) and (C) were derived from log-rank tests.et al., 2000; Todorovic-Rakovic et al., 2005). It is therefore
of great interest to identify regulators for HER-2 expres-
sion in breast cancer. In this context, Xing et al. (2000)
reported that DNA-binding protein PEA3 specifically
targets a DNA sequence on the HER-2/neu promoter
and downregulates the promoter activity. It is less clear,
however, whether genetic lesions of PEA3 can cause
HER-2 overexpression.
Foxp3 was identified during position cloning of Scurfin,
a gene responsible for X-linked autoimmune diseases in
mice and humans (immune dysregulation, polyendopathy,
enterophathy, X-linked, IPEX) (Bennett et al., 2001; Brun-
kow et al., 2001; Chatila et al., 2000; Wildin et al., 2001).
Serendipitously, we observed a high rate of spontaneous
mammary cancer. Our systemic analyses reported herein
demonstrate that the Foxp3 gene is a mammary tumor
suppressor in mice and humans. Moreover, Foxp3
represses the transcription of the HER-2/ErbB2 gene via
interaction with forkhead DNA-binding motifs in the
ErbB2 promoter.
RESULTS
Spontaneous and Carcinogen-Induced Mammary
Cancer in Foxp3sf/+ Female Mice
The mutant BALB/c mice we used for the initial study
carried mutations in two closely linked X chromosome1276 Cell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc.genes, Foxp3sf and Otcspf. During the course of the study,
a spontaneous segregation of Otcspf allowed us to obtain
a BALB/cOtcspf/+ strain. Meanwhile, we obtained an inde-
pendent line of Scurfymice that had never been crossed to
the Spf mutant mice and we backcrossed the Scurfy
mutant allele (Foxp3sf) for more than 12 generations into
the BALB/c background (Chang et al., 2005). Female
mice with only one copy of the Foxp3 gene survived to
adulthood and appeared normal within the first year of
life (Godfrey et al., 1991) with normal T cell function
(Fontenot et al., 2003, 2005; Godfrey et al., 1994). Our
extended observations of the retired breeders for up to
two years revealed that close to 90% of the Foxp3sf/+
Otcspf/+ and Foxp3sf/+ mice spontaneously developed
malignant tumors. Cancer incidences in the littermate con-
trols and a line of congenic mice with a mutation inOtc but
not Foxp3 were comparable with each other (Figures 1A
and1B). About 60%of the tumorsweremammary carcino-
mas (Figures 1A and 1C), although other tumors, such as
lymphoma, hepatoma, and sarcoma were observed. His-
tological analyses revealed lung metastasis (Figure 1A;
lower panels, based on expression of ER and/or PR, data
not shown) in about 40% of the mice with mammary can-
cer. More than a third of the tumor-bearing mice had mul-
tiple lesions in themammaryglands.Most, althoughnot all,
mammary carcinomas expressed the estrogen receptor
(ER+, 14/18) and progesterone receptor (PR+, 12/18).
Figure 2. Inactivation of the WT Foxp3
Allele in Mammary Cancer Cells
(A) Defective Foxp3 expression in breast can-
cer. RNA extracted from the cells isolated by
laser-capture microdissection was subjected
to quantitative real-time RT-PCR using primers
specific for Foxp3, Hprt, and CK19. In the left
panel, fluorescence intensity (DRn) was plotted
versus cycle number. Mean and standard devi-
ation (SD) from three individual mice per group
are presented in the right panel (p < 0.0001,
one-way ANOVA test when either internal stan-
dard was used).
(B) Immunohistochemical staining of normal
mammary glands and adenocarcinomas from
a Foxp3sf/+Otcspf/+ mouse using rabbit anti-
FOXP3 polyclonal antibody and normal rabbit
IgG as the control.
(C) Specific silencing of the WT allele in breast
cancer cells. Foxp3 transcripts were amplified
from microdissected breast cancers or normal
breast epithelium by two rounds of anchored
PCR and were cloned into the TOPO vector
and sequenced. The number of clones with
sequences of WT or mutant alleles in the breast
cancer and normal epithelium is presented. A
total of 20 clones were sequenced from each
group. Data shown are from pooled samples
that lack CD3 transcripts. n.d., not detectable.In order to focus on mammary cancer, we treated the
mice with a carcinogen, 7,12-dimethylbenz [a] anthracene
(DMBA), in conjunction with progesterone. Mice heterozy-
gous for Foxp3sf, but not those heterozygous for Otcspf,
showedsubstantially increased susceptibility tomammary
cancer, as revealed by earlier onset and increased inci-
dence (Figure 1D) and multiplicity (data not shown) of the
breast tumors. These data demonstrate that a mutation
ofFoxp3, but notOtc, results in amajor increase in suscep-
tibility to mammary carcinoma.
Foxp3 Expression in Normal and Cancerous
Mammary Tissues
Since expression of Foxp3 has not been reported in
mammary tissue, we isolated normal and cancerous cells
by laser-capture microdissection (Figure S1A) and com-
pared expression of Foxp3 and Otc by real-time RT-PCR
and histochemistry. The complete absence of the cd3
transcripts (Figure S1B) indicated that the microdissected
samples were devoid of T cells, the main cell types known
to express Foxp3 (Fontenot et al., 2005). A representative
profile and summarized data of Foxp3 expression in
Foxp3sf/+Otcspf/+ mice and age-matched wild-type (WT)
control mice are shown in Figure 2A. Foxp3 mRNA was
detected in normal mammary epithelium from both the
WT and Foxp3sf/+Otcspf/+ mice, but not in mammary
cancer cells from the same Foxp3sf/+Otcspf/+ mice. Immu-
nohistochemical staining (Figure 2B) confirmed the loss of
expression of Foxp3 in the mammary carcinoma gener-
ated from the Foxp3sf/+Otcspf/+ mice.
Foxp3 is an X-linked gene that is subject to X-chromo-
somal inactivation (Fontenot et al., 2005). We carried outan anchored RT-PCR and cloned the low levels of Foxp3
mRNA in the breast tissues. We sequenced the cDNA
clones from pooled samples after ruling out potential
T cell contamination (based on a lack of T cell specific
cd3 transcripts; Figure S1B). As shown in Figure 2C,
100% of the Foxp3 transcripts in the cancerous tissues
were from the mutant alleles, which indicate that the
wild-type allele was silenced in the tumor cells. In contrast,
the transcripts from the mutant allele constituted 15% of
the transcripts in the normal mammary samples from the
same mice. Thus, the expression pattern of Foxp3 fulfills
another criterion for a tumor suppressor gene.
FOXP3 Is a Repressor of ErbB2 Transcription
Our characterization of themammary tumors in themutant
mice revealed widespread upregulation of ErbB2, in con-
trast to those rare tumors from WT mice, as shown in
Figure 3A and Table S1. Using real-time RT-PCR, 8- to
12-fold more ErbB2 mRNA was found in the cancer cells
than in normal epithelium (Figure 3A). There was also
more ErbB2 mRNA in the Foxp3sf/+spf/+ epithelium than
in that of theWT female mice (Figure 3A), which indicates
a potential gene dosage effect of Foxp3 on the regulation
of ErbB2 expression in vivo. Transfection of the TSA cell
line with Foxp3 cDNA repressed ErbB2 levels on the
TSA cell line (Figure 3B).
Analysis of the 50 sequence of the ErbB2 gene revealed
multiple binding motifs for the forkhead domain (Fig-
ure 3C). To test whether Foxp3 interacts with the ErbB2
promoter, we used anti-V5 antibody to precipitate son-
icated chromatin from the TSA cells transfected with the
Foxp3-V5 cDNA and used real-time PCR to quantitateCell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc. 1277
Figure 3. Foxp3 Represses the Expres-
sion of ErbB2
(A) Overexpression of ErbB2 in mouse mam-
mary cancers. The left panels show immunohis-
tochemical staining of a noncancerous mam-
mary gland and an adjacent adenocarcinoma
from a Foxp3sf/+Otcspf/+ mouse using anti-
ErbB2 antibody. The right panel shows relative
expression levels of ErbB2 in normal mammary
epithelium of WT and Foxp3sf/+Otcspf/+ mice
and of cancer tissues from Foxp3sf/+Otcspf/+
mice as revealed by real-time RT-PCR of LCM
samples. Data shown are means and SD. The
expression of ErbB2 was normalized against
either Hprt or CK19. Highly significant differ-
ences were observed between cancerous and
normal tissue (p < 0.001, ANOVA test when
either internal standards were used).
(B) Transfection of Foxp3-V5 into TSA cells
repressed expression of the ErbB2 locus. The
left panel shows mRNA levels as measured
by real-time PCR. Data shown are means and
SD of triplicates. The right panel shows the
protein levels by western blot of the cell lysates
using anti-ErbB2 antibody. The amount of
actin-b was used as loading control, while the
amount of transfected Foxp3-V5 was mea-
sured by western blot using anti-V5 antibodies.
(C)Binding of the Foxp3-V5 fusionprotein to the
promoter region of theErbB2 gene. Toppanel is
a diagram of the 50 region of the ErbB2 gene, in-
cluding thepromoter, exon 1, intron 1, and exon
3. The forkhead-binding motifs are illustrated
withsmall greenbars,while the regionssurveyed
by real-time PCR are marked in red bars. The
lower panel shows the amount of DNA precipi-
tated by either control IgG or anti-V5 mAb
expressed as percentage of the total input geno-
mic DNA. Data shown are means and standard
deviation (SD) of triplicates. This experiment
has been repeated twice with similar results.
(D) Foxp3-mediated repression of the ErbB2
promotor requires forkhead-binding motifs as
evaluated by dual-luciferase reporter assay.
The promoter regions differed in the number of forkhead-binding motifs, as illustrated in the diagram on the left. Three different cell lines were
transfected with either vector control or Foxp3 (1 mg/well) in conjunction with the luciferase reporter driven by different 50 promoter regions of the
ErbB2 gene (0.6 mg/well). pRL-TK was used as internal control. The luciferase activity from the cells transfected with the pGL2-basic vector was
arbitrarily defined as 1.0. Data shown are means and SD of triplicates and have been repeated at least three times.
(E) Site-directed mutagenesis of one of two conserved regions with multiple forkhead-bindingmotifs in the ErbB2/HER-2 promoter prevented repres-
sion of the ErbB2 promoter by Foxp3. The two binding sites, as illustrated in Figure S2, were deleted individually (deleted DNA sequence, Mut A:
AAATCTGGGATCATTTA; Mut B: TTTGAATTTCAGATAAA). Mutations of either site prevented FOXP3-mediated suppression. The promoter activity
was measured and normalized as detailed in (D), except that the amount of promoter DNA was 0.4 mg/sample. The promoter activities of the vector
groups were artificially defined as 1.0. Data shown are means and SD of triplicates. This experiment has been repeated twice with similar results.
(F) Foxp3-mediated binding to specific cis elements in the ErbB2 promoter. Nuclear extracts from the Foxp3-V5- (F-NE) or vector-transfected control
(C-NE) TSA cells were preincubated with 32P-labeled WT (*W) or mutant probes (*M) in the presence of an unlabeled WT (W) or mutant probe (M). The
mixtures were analyzed by PAGE. NS, nonspecific; FP, free probe. The specific Foxp3-shifted band is marked by an arrow. Data shown have been
repeated three times.
(G)Mutation of forkheadbindingmotifs (Mut 4) abrogatedFOXP3-mediated repression, but not basal promoter activity. This is as in (E), except thatWT,
Mut B, andMut 4 (mutations that inactivate the Foxp3 binding as detailed in [F]) of theErbB2 promoterswere used. This experiment has been repeated
twice with similar results. The differences were compared by student t tests with p value provided. Data shown are means and SD of triplicates.the amounts of the specific ErbB2 promoter region precip-
itated by the anti-V5 antibodies in comparison to those
that bound to mouse IgG control. As shown in
Figure 3C, the anti-V5 antibodies pulled down significantly
higher amounts of ErbB2 promoter DNA than the IgG1278 Cell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc.control, with the highest signal around 1.6 kb 50 of the tran-
scription starting site.
To test whether the binding correlated with the suppres-
sion by Foxp3, we produced luciferase reporter using the
1.8, 1.2, and 0.8 Kb upstream of the ErbB2 TSS and tested
Figure 4. Characterization of FOXP3
Transcripts in Primary, Immortalized,
and Malignant Mammary Epithelial Cells
Relative levels and isoforms of FOXP3 (the
upper panel) and HER-2 (the lower panel)
mRNA. After normalizing against endogenous
GAPDH, the amounts of transcripts were com-
pared to those found in HMEC-1, which was
arbitrarily defined as 1.0. Data shown are
means and SD of triplicates. This experiment
has been repeated twice with similar results.
The reported ER status and the isoforms of
the FOXP3 transcripts detected are indicated.
To characterize the isoforms, FOXP3 mRNA
was amplified by two rounds of anchored
PCR using primers annealing to exons 1 and
12. The bulk PCR products were sequenced
only if one species was found in agarose
electrophoresis. When more than one species
was observed, the PCR products were cloned
and multiple clones were sequenced until all
of the species observed in the agarose gel
were identified.the ability of Foxp3 to repress ErbB2 promoter activity. In
three separate cell lines, we observed that the region with
the strongest ChIP signal was required for optimal-
repression by Foxp3 (Figure 3D). Furthermore, we deleted
two potential Foxp3 binding sites based on intensity of
ChIP signal, abundance of consensus binding sites, and
conservation between mouse and human (Figure S2) by
site-directed mutagenesis and measured the effect on
Foxp3-mediated repression. As shown in Figure 3E,
deletion of either binding site substantially increased the
ErbB2 promoter activity in the presence of Foxp3 and
thus alleviated Foxp3-mediated repression.
Since the region deleted in Mut B is 100% conserved
between mouse and man and since this deletion
completely wiped out repression, we used an electropho-
retic mobility shift assay (EMSA) to determine whether the
forkhead DNA-binding motifs in region B bound to Foxp3.
As shown in Figure 3F, the nuclear extracts from the
Foxp3-expressing cells specifically retarded migration of
the WT but not mutant 32P-labeled probes compared
with control cells. While mutant cold probes did not affect
Foxp3-binding activities, WT cold probes significantly
diminished them, establishing that the binding of these
complexes is specific to forkhead DNA-binding motifs.
We therefore carried out site-directed mutagenesis to
replace the 12 nucleotides (Mut C) within the ErbB2
promoter and compared the promoter activity and
Foxp3-repression by luciferase assays. While the
wild-type promoter was repressed by Foxp3, no
repression by Foxp3 was observed when the mutant
promoter was used. Moreover, in contrast to the
deletional Mut B, the mutations had no impact on
the basal activity of the ErbB2 promoter (Figure 3G).
Taken together, our new data make a compelling
case that Foxp3 represses the ErbB2 promoter via
specific forkhead-binding motifs.FOXP3 Defects in Human Breast Cancer
We analyzed the levels and isoforms of the FOXP3 tran-
scripts in a panel of normal human mammary epithelial
cells (HMEC), an immortalized but nonmalignant cell line
(MCF-10A), and ten malignant breast cancer cell lines dif-
fering in ER/PR andHER-2 status. Early passage of HMEC
with no methylation in the CpG island of the P16 promoter
(Figure S3) was used to avoid effects associated with P16
inactivation in postsenescence HMEC cultures (Romanov
et al., 2001). As shown in Figure 4A, similar levels of
FOXP3 transcripts were observed in two independent iso-
lates of HMEC and in the immortalized cell line MCF-10A.
Each of the ten tumor cell lines had a different degree of
reduction in FOXP3 mRNA levels in comparison to
HMEC and MCF-10A. Among them, two were completely
devoid of FOXP3mRNA, while the others had a 1.5- to 20-
fold reduction. We then used anchored primers spanning
exons 1–12 to amplify the FOXP3 transcripts, and then we
sequenced the PCR products. As shown in Figure 4, none
of the tumor cell lines expressed full-length FOXP3 tran-
scripts. The HMEC expressed the same two isoforms as
observed in the T cells, while MCF-10A expressed the
exon 3-lacking isoforms. The same isoform was also
found in four tumor cell lines at much lower levels. In addi-
tion, three tumor cell lines expressed an isoform lacking
both exons 3 and 4. The alternative splicing resulted in
a frameshift beginning at codon 70 and an early termina-
tion at codon 172. Furthermore, two tumor cell lines
expressed a FOXP3 isoform lacking exons 3 and/or 8.
Exon 8 encodes the leucine-zipper domain that is fre-
quently mutated in IPEX patients (Ziegler, 2006). Thus,
FOXP3 is abnormal in breast cancer cell lines. Consistent
with a role for FOXP3 in repressing HER-2 expression, the
majority of the breast cancer cell lines had higher levels of
HER-2 in comparison to normal HMEC (Figure 4, lower
panel). However, additional changes are also likelyCell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc. 1279
Figure 5. FOXP3 Defects in Human
Breast Cancer
(A) Downregulation of the FOXP3 protein
among human breast cancer cells. Photo-
graphs in the top panels show anti-FOXP3
staining of normal and carcinoma tissues from
the same patient, with specificity control shown
at the bottom. The number and percentage of
FOXP3 positive tissues are shown in the right
panel. Samples with nuclear staining by the
anti-Foxp3 antibody were scored as positive.
(B) Deletion of the FOXP3 locus in breast cancer
cells. Breast cancer tissue microarray samples
were analyzed by FISH using three BAC clone
probes surrounding a 10 MB region in Xp11.2.
A typical FISH for the CEPX (green) and
FOXP3 (orange) probes is shown on the left,
while the genomic structure of the X chromo-
some and probe positions are illustrated in the
middle panel. A total of 238 samples were ana-
lyzed for all probes, with 223 samples providing
definitive FISH data. Twenty-eight of the two
hundred and twenty-three samples showed
deletions as detected by at least one of the
three probes. The positions of the deletions in
the 28 samples are summarized in the right
panel.
(C) Somatic mutation of the FOXP3 gene in
breast cancer samples: summary of sequenc-
ing data from 65 cases, including 50 formalin-
fixed samples and 15 frozen samples. Genomic
DNA was isolated from matched normal and
cancerous tissues from the same patients
and amplified with primers for individual exons
and intron-exon boundary regions. Somatic
mutations were identified by comparing
sequences from normal and cancerous sam-
ples from the same patients. The data are
from either bulk sequencing of PCR products
or from the sequencing of 5–10 clones from
PCR products. Only those mutations that
were observed in multiple clones were scored. Mutations identified from 50 cases of formalin-fixed samples are marked in black, while those iden-
tified from 15 cases of frozen tissue samples are marked in red.
(D) FOXP3 mutations reduced its repressor activity for the HER-2 promoter in the SKBr-3 cell line. The left panel shows expression of mutant
cDNA. The middle panel shows luciferase activity, while the right panel shows the levels of HER-2 transcripts. The difference between WT and
318 P > L and that between WT and 204C > R205E > K are highly significant (p < 0.01). Data shown are means and SD of triplicates and
representative of at least two to three independent experiments.
(E) A breast cancer sample with a somatic mutation in intron 6 (case 23) had an inactivated FOXP3 locus. Normal mammary epithelial (N) and
tumor (T) cells were isolated by LCM. The FOXP3 transcripts were determined either by PCR using primers spanning exons 5–8 to detect alter-
natively spliced products or by real-time PCR using primers spanning exons 10–12. The upper and middle panels show photographs of PCR prod-
ucts of FOXP3 or GAPDH loci, while the right panel shows the relative level of FOXP3 transcripts as determined by real-time PCR. Neither assay
detected any FOXP3 transcripts in the tumor of case no. 23. Substantial amounts of FOXP3 transcripts were detected in normal samples and
tumors in case no. 22 (with a synonymous mutation in exon 7), which was artificially defined as 1.0. Data shown are means and SD of triplicates.
This experiment has been repeated twice with similar results.required for HER-2 overexpression, as three cell lines did
not overexpress HER-2 even though the FOXP3 tran-
scripts were greatly reduced.
We took three approaches to determine whether the
findings in the mutant mice and human breast cancer
cell lines are relevant to the pathogenesis of human breast
cancer. First, we used immunohistochemistry to deter-
mine expression of FOXP3 in normal versus cancerous
tissue. As shown in Figure 5A, while about 80% of the
normal breast samples expressed FOXP3 in the nuclei of1280 Cell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc.the epithelial cells, only about 20% of the cancerous
tissue showed nuclear staining. Second, we used fluores-
cence in situ hybridization (FISH) to determine whether the
FOXP3 gene was deleted in the breast cancer samples.
The minimal common region of deletion was identified
using flanking p-telomeric and centromeric clones. Out
of 223 informative samples, we observed 28 cases
(12.6%) with deletions in any of the three loci. Interest-
ingly, deletion of the FOXP3 locus was found in all of the
28 cases (Figure 5B and Table S2). These data suggest
that FOXP3 is likely within the minimal region of deletion in
the Xp11 region studied. Although all deletions were het-
erozygous, the FOXP3 protein was undetectable in 26
out of 28 cases. Thus, it appears that for the majority of
the breast cancer samples, LOH alone was sufficient to in-
activate the locus, perhaps due to X-chromosomal inac-
tivation. The two cases with both deletion and FOXP3
expression had X polysomy with three and four X chromo-
somes, respectively (Table S2). Thirdly, we isolated DNA
from matched normal and cancerous tissues (50 cases
with formalin-fixed samples and 15 cases of frozen sam-
ples) from patients with invasive ductal carcinoma and
amplified all 11 coding exons and intron-exon boundary
regions by PCR. Two independent PCR products were
sequenced in order to confirm the mutations. Unless the
bulk sequencing data were unambiguous (Figures S4A
and S4C), the PCR products were cloned, and five to
ten independent clones from each reaction were se-
quenced (Figure S4B). Among the formalin fixed samples,
we only used the cases in which the normal tissue sam-
ples gave unambiguous sequencing data that matched
the wild-type FOXP3 sequence. When the cancerous tis-
sues were compared with normal tissues from the same
patient, 36% (18 out of 50 formalin-fixed samples and
5 out of 15 frozen samples) showed somatic mutations
(Table S3). Loss of the wild-type allele was found in
6 out of 23 cases (38%) of cancer samples with somatic
FOXP3 mutations (see Figure S4C for an example). The
other cases had heterozygous mutations (Figure S4A).
Eighteen mutations resulted in the replacement of amino
acids. Most are likely to be critical for FOXP3 function,
as judged from the pattern of mutation in IPEX patients
(Ziegler, 2006) or in the conserved zinc finger domain
that has so far not been implicated (Figure 5C).
Although most samples had a single mutation of the
FOXP3 gene, we did observe two cases with multiple mu-
tations. In the first sample (Figure S4B; case 3 in Table S3),
the twomutations occurred in consecutive codons, result-
ing in two nonconservative replacements of amino acid
residues. Clonal analysis revealed that both mutations oc-
curred in the same clone (Figure S4B). In the second sam-
ple (Table S3; case 16), three mutations occurred in intron
11. Since this case lacked a WT allele (Figure S4D), it is
likely that all of the mutations occurred in the same allele.
The possibility of a mismatch in the cancer and normal
samples was ruled out by comparing the normal and can-
cer samples for polymorphism of two unrelated genes
(data not shown).
To directly test whether FOXP3 mutations affect the
repressor activity for theHER-2 gene, we chose two repre-
sentative somatic FOXP3 mutants isolated in the cancer
cells and tested their repressor activity for the HER-2
promoter. Onemutation (338P > L) resided in the signature
forkhead domain, which is often mutated in the IPEX pa-
tient, while the other double mutation (204C > R205E > K)
was from the zinc finger domain that has not been
implicated in IPEX patients. As shown in Figure 5E, both
mutations significantly reduced the repressor activity ofFOXP3. The reduced repression of the HER-2 promoter
correlates with a significantly reduced inhibition of HER-2
mRNA (Figure 5D).
Four cases hadmutations in introns that may potentially
affect RNA splicing. We used laser-guided microdissec-
tion to isolate normal and cancerous epithelial cells from
one case with a mutation in intron 6 (case 23; Table S3).
RNA was isolated and tested for the potential effects of
the mutation on RNA splicing (using primers on exons 5
and 8) and total FOXP3 transcript, as quantitated by
real-time PCR using primers spanning exons 10–12. Tis-
sues from another patient with a mutation in exon 7
were used as control. As show in Figure 5E’s left panel,
primers spanning exons 5 and 8 failed to detect FOXP3
mRNA from the cancerous tissue of case no. 23. Further-
more, primers spanning exons 10–12 also failed to detect
any FOXP3 transcripts. Substantial levels were detected
in the normal epithelial cells of the same patients as well
as in normal and cancerous tissues from case no. 22.
Since the wild-type allele had been lost in the cancer cells
of case no. 23, it is likely that the mutation in intron 6 in-
activated FOXP3. With an intron of 944 nucleotides,
a mutation that prevented splicing of intron 6 would cause
premature-termination codon-mediated RNA decay,
which is operative in the FOXP3 gene (Chatila et al.,
2000).
FOXP3 Defects and HER-2 Overexpression
To demonstrate a role for FOXP3 defect in HER-2 over-
expression, we first silenced the FOXP3 gene in early
passage of primary HMEC (Supplemental Fig. S3) using
a lentiviral vector expressing FOXP3 siRNA. As shown in
Figure 6A, the FOXP3 siRNA reduced FOXP3 expression
by more than 100-fold while increasing HER-2 mRNA by
7-fold. A corresponding increase in cell surface HER-2
was also observed (Figure 6B). These results implicate
FOXP3 as a repressor of HER-2 in human breast epithelial
cells.
Second, since a major mechanism for HER-2 upregula-
tion in breast cancer is gene amplification (Kallioniemi
et al., 1992), an intriguing issue is whether FOXP3 is capa-
ble of repressing HER-2 in cancer cells with an amplified
HER-2 gene.Weproduced aTet-off line of BT474, a breast
cancer cell line known to have HER-2 gene amplification
(Kallioniemi et al., 1992), and transiently transfected it
with a pBI-EGFP-FOXP3- vector. After drug selection,
the cells were cultured either in the presence or absence
of doxycycline. While the cells cultured with doxycycline
did not express FOXP3 (data not shown), removal of doxy-
cycline resulted in induction of FOXP3 in a significant frac-
tion of the cancer cells, which allowed us to compare
HER-2 levels in the FOXP3+ and FOXP3 cells in the
same culture by flow cytometry. As shown in Figure 6C,
FOXP3 cells had about a 5- to 10-fold higher level of
the HER-2 protein on the cell surface in comparison to
the FOXP3+ cells.
Thirdly, we compared the expression of FOXP3 with
HER-2 expression in breast cancer tissues. As shown inCell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc. 1281
Figure 6. FOXP3 Is an Important HER-2 Repressor
(A) Silencing of FOXP3 resulted in the upregulation of HER-2 in primary human mammary epithelial cells (HMEC). Early passage of HMEC were trans-
ducedwith lentiviral vector for either control sequence or FOXP3 siRNA. The untransfected cells were removed by selection with blasticidin. At 1week
after transduction, the levels of the FOXP3 andHER-2 transcripts were quantitated by real-time PCR. Data shown are mean and standard error of the
mean of relative levels of transcripts (with that in the vector-transduced cells defined as 1.0) and represent those of three independent experiments.
(B) Flow cytometry data showing the effect of FOXP3 silencing on HMEC surface HER-2 levels. HER-2-negative MDA-MB468, HER-2lo MCF-7 and
HER-2hi SKBr3 cell lines were included for comparison.
(C) In the Tet-off inducible FOXP3-expressing BT474, FOXP3 repressed HER-2. BT474 cells were first transfected with pTet-Off vector. The trans-
fectants were selected by both blasticidin and G418 in doxycycline-containing medium. The drug-resistant cells were cultured in the absence of
doxycycline for 5 days to induce FOXP3. The cells were stained for FOXP3 and HER-2 proteins by flow cytometry. Data shown are histograms
depicting HER-2 levels among the gated FOXP3hi and FOXP3 cells based on reactivity to the anti-Foxp3 antibody and are representative of those
from two independent experiments.
(D) Inverse correlation between FOXP3 expression (the top panel) and that of the HER-2 (middle panel) among the human breast cancer samples.
Tissue microassay samples were stained with either anti-FOXP3 antibodies or anti-HER-2 antibodies and were scored by two different pathologists
in a double-blind fashion. FOXP3 staining was scored by nuclear staining with affinity-purified anti-FOXP3 antibodies. A summary of 517 FOXP3+ and
145 FOXP3 samples is shown in the bottom panel.
(E) Inverse correlations between FOXP3 expression and HER-2 scores in cells with or without HER-2 amplification. The HER-2 gene-copy number
was determined by FISH, while nuclear expression of FOXP3 was determined by immunohistochemistry. Data shown are mean and SD of HER-2
scores of 425 cases of breast cancers grouped by HER-2 copy number. P values were generated by the Mann-Whitney test.Figure 6D, downregulation of FOXP3 was strongly associ-
ated with the overexpression of HER-2, which supports
a role for FOXP3 inactivation in HER-2 overexpression in
breast cancer. Nevertheless, since many of the FOXP3
cells remained HER-2, it is likely that disregulation
of FOXP3 is insufficient for HER-2 upregulation. On the
other hand, since only 3 of 82 FOXP3+ cancer cells ex-
pressed high levels of HER-2, FOXP3 inactivation is
likely important for HER-2 upregulation under most
circumstances.
Fourth, we divided breast cancer samples based on
their HER-2 gene copy numbers and compared the
FOXP3+ and FOXP3 cancer samples for the relative1282 Cell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc.amounts of cell surface HER-2 expression. As shown in
Figure 6E, in each of the gene-dose categories, FOXP3+
samples had reduced HER-2 scores in comparison to
the FOXP3 samples. These results strongly suggest
a critical role for FOXP3 in repressing HER-2 expression
even in the cases of HER-2 gene amplification.
Fifth, of the 223 informative samples among the 238 that
we screened for Xp11.2 deletions, those with deletions
encompassing the FOXP3 locus had significantly higher
HER-2 scores compared to those without deletions
(p = 0.03) (Table S4). Likewise, we compared the relative
HER-2 scores among the 50 samples in which we had
sequenced all FOXP3 exons. As shown in Table S5, the
Figure 7. Foxp3 Inhibits the Growth and Tumorigenicity of Multiple Breast Cancer Cell Lines
(A) Breast cancer cell lines MCF-7, SKBr3, and TSA were transfected with equal concentrations of vector alone (Vector), Foxp3, or Otc cDNA. After
3 weeks of G-418 selection, the drug-resistant clones were visualized by crystal violet dye.
(B) Summary of the colony numbers in three independent experiments as described in (A). Data shown are means and SD.
(C) Somaticmutations identified frombreast cancer samples attenuated the growth suppression of the FOXP3. This is as in (A) and (B), except that two
somaticmutants were comparedwithWT FOXP3 cDNA using the two human breast cancer cell lines. Data shown aremeans and SDof triplicates and
are representative of two independent experiments. Expression of WT and mutant proteins at 1 week after transfection is presented in the insert.
(D and E) Ectopic expression of the ErbB2 but not the c-Myc cDNA abrogated Foxp3-mediated repression. TSA cells were transfected with either
pcDNA6-blasticidin vector or ErbB2 cDNA and selected with blasticidin for 2 weeks. Pools of blasticidin-resistant cells were supertransfected
with the pEF1-G418 vector or Foxp3 cDNA. The cells were then plated and selected with blasticidin and G418 for 3 weeks. The viable colonies
were visualized after staining with the crystal violet dye. Shown in (D) are photographs of a representative plate showing abrogation of Foxp3-medi-
ated suppression by ErbB2. Shown in (E) are the mean and SD of the colony numbers. This experiment has been repeated twice with essentially iden-
tical results.
(F) Expression of Foxp3 reduced growth rate of tumors. Syngeneic BALB/c mice were injected with 53 105/mouse Foxp3 or vector-transfected TSA
cells in the flank, and the sizes of the local tumor mass were measured using a caliper. Data shown are means and SD and have been repeated once.
(G) The survival of tumor-bearing mice was monitored over a 7-week period (p = 0.0015, log-rank test). As in (F), except that 106 tumor cells/mouse
were injected, and the mice were euthanized when they became moribund.mutations in the FOXP3 gene correlated with higher levels
of HER-2 (p = 0.0083).
Foxp3/FOXP3 Inhibits Tumorigenicity of Breast
Cancer Cells
To test whether the Foxp3 gene can suppress the growth
of breast cancer cells, we transfected the empty vector or
the vectors carrying either Foxp3 (mouse or human origin)
or Otc cDNA into three breast cancer cell lines, including
mouse mammary tumor cell line TSA or human breast
cancer cell lines MCF7 (ER+HER-2low, no HER-2 amplifi-
cation) and SKBr3 (ERHER-2high with HER-2 amplifica-
tion). The untransfected cells were removed by a selec-
tion with G418. While the vector-transfected cells grew
rapidly, the Foxp3-transfected cell lines seldom grew
into large colonies. The Foxp3-transfected culture hada drastic reduction in both the size and the number of
the drug-resistant colonies. No effect was observed
when the Otc cDNA was used (Figures 7A and 7B).
To test whether the somatic mutations uncovered from
cancerous tissues ablated their growth inhibition, we
transfected WT and two mutant Foxp3 cDNA into SKBr3
and MCF7 cell lines. As shown in Figure 7C, in both cell
lines, the mutants had a greatly reduced ability to sup-
press tumor growth.
To test whether repression of ErbB2 explains the tumor
suppressor activity of the Foxp3 gene in the ErbB2+ can-
cer cell line, we transfected TSA cells with mouse CMV
promoter-driven ErbB2 cDNA cloned into the pcDNA6
vector and evaluated their susceptibility to Foxp3-medi-
ated growth suppression. In this setting, the expression
of ErbB2 was resistant to Foxp3-mediated repressionCell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc. 1283
(data not shown). If repression of endogenous ErbB2 is
critical for Foxp3-mediated tumor suppression, ectopic
expression of ErbB2 should alleviate the growth inhibition
by Foxp3. As shown in Figures 7D and 7E, while the
pcDNA6-vector-transfected TSA cells remained suscepti-
ble to Foxp3-mediated repression, the ErbB2-transfected
TSA cells were completely resistant. In contrast, transfec-
tion of c-Myc barely alleviated the growth inhibition by
FOXP3 (Figure 7E). These results suggest that Foxp3 sup-
presses TSA growth by repressing transcription of ErbB2.
We transfected TSA cells with either empty vector or
V5-tagged Foxp3 cDNA. The stable transfectant cell lines
were selected by G-418. The vector and Foxp3-V5-trans-
fected cell lines were injected into syngeneic BALB/c
mice, which were then observed for tumor growth and
mouse survival. As shown in Figure 7F, Foxp3-transfec-
tants showed reduced growth in vivo. The mice that
received TSA-vector cells became moribund earlier with
higher incidence, while about 50% of the mice that
received the Foxp3-V5-transfected cells survived more
than 7 weeks (Figure 7G). Similarly, Foxp3-transfected
4T1, a mouse mammary cancer cell line with ErbB2 over-
expression, also showed reduced tumorigenicity in vivo
(data not shown).
DISCUSSION
Foxp3 Is an X-Linked Mammary Tumor
Suppressor Gene
Serendipitously, we observed that mice heterozygous for
the Foxp3 mutation spontaneously developed mammary
cancer at a high rate. Since two independently maintained
lines sharing the Foxp3 mutation have a comparably
higher incidence of mammary cancer, the Foxp3mutation
is likely responsible for the increased rate of breast can-
cer. Unlike essentially all cancer suppressor genes identi-
fied to date, Foxp3 is X-linked and inactive in cells in which
theWT allele was silenced by X inactivation. This is indeed
the case, as the low levels of Foxp3 transcripts in the can-
cer cells were derived exclusively from the mutant alleles.
Our analysis of human breast cancer samples provides
strong support for an important role for the FOXP3 gene in
the development of breast cancer. First, we searched
X-chromosomal deletion using three markers encom-
passing more than 10 MB of Xp11 and found that
FOXP3 is likely the minimal region of deletion. Second,
we revealed a high proportion of somatic mutations in
the FOXP3 gene (23 of 65 cases over about 2000 bp
exon and intron sequence scanned). The significance of
our finding can be discerned indirectly based on the fact
that the mutations tended to cluster around important do-
mains, such as the forkhead and the zinc finger domains.
In addition, most of the mutations resulted in the noncon-
servative replacement of amino acids, and cancers with
mutations identified had higher levels of HER-2 than those
without mutations. The rate of missense to synonymous
mutation was 18/3, which greatly exceeds what would
be predicted if the mutations were not relevant to tumor1284 Cell 129, 1275–1286, June 29, 2007 ª2007 Elsevier Inc.development. More importantly, we demonstrated that
two tested mutations in the FKH and zing finger domains
inactivated the repressor activity and tumor growth inhibi-
tion and that cancer tissues bearing an intronic mutation
had an inactive FOXP3 locus. Moreover, mutations and
deletions of the FOXP3 locus corresponded to increased
HER-2 levels. Third,wehavedocumentedextensive down-
regulation of FOXP3 among more than 600 cases of
breast cancer tissues.
Foxp3 Is a Major Transcriptional
Repressor for ErbB2
The molecular lesions leading to HER-2 overexpression
remain poorly understood. Here we showed that the
Foxp3 mutation resulted in overexpression of ErbB2, the
murine homolog of HER-2. In addition, transfection of
Foxp3 repressed ErbB2 transcription. More importantly,
chromatin immunoprecipitation and EMSA analyses
revealed that Foxp3 binds specifically to its consensus
sequence in the 50 of the ErbB2 gene. Since specific
mutations in the promoter abrogate its susceptibility to
repression by Foxp3, such binding is likely responsible
for it.
Importantly, we have demonstrated that for TSA cell
line, which has ErbB2 overexpression, repressing the
ErbB2 locus is responsible for Foxp3’s tumor suppressor
activity. The requirement for continuous expression of
ErbB2 is best explained by the concept of oncogene
addiction (Weinstein, 2002). However, FOXP3 can also
suppress the growth of tumor cell lines that do not grossly
overexpress HER-2/ErbB2, such as MCF-7. In an effort to
identify other potential FOXP3 targets, we have produced
a FOXP3-Tet-off MCF-7 cell line that expresses FOXP3
upon removal of tetracycline (Figure S5A). Using the
most current version of Entrez gene-based CDFs for
a more accurate GeneChip analysis (Dai et al., 2005), we
uncovered widespread changes in the expression of
genes that are involved in several pathways critical for
cancer cell growth (Figure S5B). Interestingly, ten genes
involved in ErbB2 signaling pathway were repressed by
FOXP3 (Figure S5C). Thus, multiple oncogenes can
potentially be upregulated by FOXP3 inactivation. Taken
together, we have demonstrated that FOXP3 is the first
X-linked breast cancer suppressor that represses the
HER-2/ErbB2 oncogene. Given the significant role of
HER-2 in the pathogenesis of human breast cancer and
the widespread defects of the FOXP3 locus, it is likely




Relative quantities of mRNA expression were analyzed using real-time
PCR (Applied Biosystems ABI Prism 7700 Sequence Detection Sys-
tem, Applied Biosystems). The SYBR (Qiagen) green fluorescence
dye was used in this study. The primer sequences (50-30) are listed in
Table S6.
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation was carried out according to pub-
lished procedure (Im et al., 2004). Briefly, the Foxp3-V5-transfected
TSA cells were sonicated and fixed with 1% paraformaldehyde. The
anti-V5 antibodies or control mouse IgG were used to pull down chro-
matin associated with Foxp3-V5. The amounts of the specific DNA
fragment were quantitated by real-time PCR and normalized against
the genomic DNA preparation from the same cells.
FOXP3-Silencing Lentiviral Vector
The lentivirus-based siRNA expressing vectors were created by
introducing the murine U6 RNA polymerase III promoter and a murine
phosphoglycerate kinase promoter (pGK)-driven EGFP expression
cassette into a vector of pLenti6/V5-D-TOPO backbone without
CMV promoter. A hairpin siRNA sequence of FOXP3 (target sequence
at the region of 1256–1274 nucleotides; 50-GCAGCGGACACTCAAT
GAG-30) was cloned into the lentiviral siRNA expressing vectors by
restriction sites of ApaI and EcoRI.
Immunohistochemistry and Fluorescence
In Situ Hybridization (FISH)
HER-2 expression was performed using Pathway HER-2 (Clone CB11)
(Ventana Medical Systems, Inc., Tucson, AZ) on the BenchMark XT
automated system per the manufacturer’s recommended protocol.
The HER-2 levels were scored by commonly used criteria (Yaziji
et al., 2004).
FISH for FOXP3 deletion was done using BAC clone RP11-344O14
(ntLocus X: 48,817,975–48,968,223), which was verified by PCR to
contain the FOXP3 gene. The minimal common region of deletion
was done using flanking p-telomeric and centromeric clones, RP11-
573N21 (ntLocus X: 43,910,391–44,078,600) and RP11-353K22 (ntLo-
cus X: 54,416,890–54,545,788), respectively.
EMSA
Nuclear extracts were prepared as described previously (Wang et al.,
1999). The sequence for the WT probe (W) was AGTTCAATTTG
AATTTCAGATAAACG. Mutant probe (M) (AGTTCAGCGCGAGCGC
CAGAGCGCCG) with mutations of all three potential forkhead binding
sites was used as specificity control.
Supplemental Data
Supplemental Data include six tables, five figures, Supplemental
Experimental Procedures, and Supplemental References and can be
found with this article online at http://www.cell.com/cgi/content/full/
129/7/1275/DC1/.
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